PROTON THERAPY FOR EARLY-STAGE LUNG CANCER

Clinical Technology
/
07.04.2015

High-dose hypofractionated PT has proven to be safe and effective for central and peripheral early-stage non-small cell lung cancer, according to a 12-year experience achieved at Loma Linda University Medical Center.

“Early-stage lung cancer” is a term used to describe patients diagnosed as having a solitary pulmonary nodule, implying the lack of direct extension into adjacent structures and no metastatic disease. The standard treatment approach for this pathology is complete surgical resection, but some patients are sometimes not eligible due to common underlying conditions such as chronic obstructive pulmonary disease or cardiac insufficiency. The offered treatment for those patients is radiation therapy.

More than 100 patients were enrolled in a clinical trial at Loma Linda and analyzed for treatment outcomes after proton therapy. High-dose hypofractionated PT achieved excellent outcomes for the treatment of lung carcinomas, with no significant complications, no required steroid therapy after treatment for radiation pneumonitis, and well maintained pulmonary function.

Share

Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies